Maria Rosaria Diadema

Learn More
We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients with MBC were enrolled in a first-line combination therapy study with oral gefitinib (250 mg(More)
Anthracyclines are among the most active antineoplastic drugs developed to date, used both in the treatment of solid cancers, such as breast and ovarian cancer and sarcomas, and of hematologic cancers. However, their clinical use is limited by cardiotoxicity, which is observed at a range of 0.4-41%. The risk of this side effect can be minimized by using(More)
Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, igf-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (vegfc). In the present study,(More)
Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, associated with unfavorable clinical characteristics in breast cancer. The aim of this study was to evaluate different angiogenic markers in endocrine-positive breast cancer patients. The authors analyzed serum and tumor samples from 71 patients with endocrine-positive(More)
725 Background: The orally active EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) gefitinib ('Iressa', ZD1839) has antitumor activity and additive or synergistic activity when combined with docetaxel in preclinical models (Clin Cancer Res 2000; 6: 2053-63). This Phase II study investigated gefitinib and docetaxel as first-line(More)
Cancer and its related therapies are acquired thrombophilic risk factors. Patients with a malignancy can suffer a thrombotic complication such as deep venous thrombosis (DVT) in the lower extremities with a possible following pulmonary embolism. Recently, an increased association between upper extremity DVT and malignancy has been observed and several risk(More)
The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer (AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85 mg m(-2) on(More)
We describe a case of spontaneous internal jugular vein thrombosis occurring as the first sign of occult lung cancer. The peculiarity of the case was the unusual site of thrombosis and the lack of risk factors for DVT (only a moderated reduction of protein S without inherited thrombophilia) as well as the absence of clinical signs of cancer. This report(More)
The value and development of the copper and magnesium have been examined in thirty-four patients whose eighteen were affected by malignant lymphomas (9 L.H. and 9 non-H.), fourteen by solid tumors and two by acute leukemias. Our results prove clearly a manifest increase of the copper in the lymphomas' patients, especially in the Hodgkin's disease, and in(More)
OBJECTIVE To assess the correlation between presurgery neutrophil to lymphocyte ratio (NLR) and distant metastasis-free survival (DMFS) in patients with early breast cancer. DESIGN Retrospective analysis. PARTICIPANTS 300 Caucasian patients with early (T1-2, N0-1, non-metastatic) breast cancer who were followed from July 1999 to June 2015 at our(More)